GAIA-102 (fulamleucel) (ip)
Gastric Cancer, Pancreatic Cancer
Early clinical trialActive
Key Facts
Indication
Gastric Cancer, Pancreatic Cancer
Phase
Early clinical trial
Status
Active
Company
About GAIA BioMedicine
A biotech company developing off-the-shelf, non-genetically modified NK-like cell therapies to eliminate solid tumors.
View full company profile